Trials
6 active
6 in total · 4 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SR-8541A administered orally in combination with intravenous botensilimab and balstilimab”In the company’s words, NCT06589440 on ClinicalTrials.gov
- Tested for
- Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), Advanced / Metastatic Solid Tumor
- Main trialPhase 2
- “This is an open-label, dose escalation and expansion, multi-center phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combination with intravenous botensilimab and balstilimab in subjects with MSS-CRC with and without active liver metastases.”In the company’s words, NCT06589440 on ClinicalTrials.gov
- Other names
- Botensilimab · Balstilimab
Other drugs for Advanced / Metastatic Solid Tumor
- PembrolizumabMerck & Co. · Phase 3
- EIK1001Eikon Therapeutics · Phase 2/3
- QL2107Qilu Pharmaceutical · Phase 3
- IFx-Hu2.0TuHURA Biosciences, Inc. · Phase 2/3
- FutibatinibTaiho · Phase 2/3
- MB11mAbxience Research S.L. · Phase 3
Coming up1
- 31 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Jul 2027 | Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) | |
| Phase 1Recruiting | Dec 2025 | A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors | |
| Phase 2Authorised | not given | WINDOW-OF-OPPORTUNITY UMBRELLA PLATFORM TRIAL OF SHORT-COURSE PRE-OPERATIVE OR NEOADJUVANT TARGETED TREATMENT IN PATIENTS WITH MOLECULARLY SELECTED AND RESECTABLE PRIMARY COLORECTAL CANCER: THE UNICORN STUDY | |
| Phase 2Authorised | not given | Pan-tumor neoadjuvant basket study of immune check-point inhibition and novel IO combinations (NEOASIS) | |
| Phase 3Authorised | not given | CIME - Combination of Immune checkpoint in locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas : A multicenter, randomised, comparative, open-label Phase III aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combination of Immune checkpoint inhibitors (botensilimab + balstilimab) versus the standard of care (FOLFOX/XELOX + nivolumab) | |
| Phase 2Authorised | not given | A phase 2, open label study to evaluate safety and clinical activity of balstilimab in monotherapy in patients with advanced/metastatic non-melanoma skin cancers (AGENONMELA). |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026